Gene silencing via heterochromatin formation plays a major role in cell differentiation and maintenance of homeostasis. Here we report the identification and characterization of a novel heterochromatinization factor in vertebrates, bromo adjacent homology domaincontaining protein 1 (BAHD1). This nuclear protein interacts with HP1, MBD1, HDAC5, and several transcription factors. Through electron and immunofluorescence microscopy studies, we show that BAHD1 overexpression directs HP1 to specific nuclear sites and promotes the formation of large heterochromatic domains, which lack acetyl histone H4 and are enriched in H3 trimethylated at lysine 27 (H3K27me3). Furthermore, ectopically expressed BAHD1 colocalizes with the heterochromatic inactive X chromosome (Xi). The BAH domain is required for BAHD1 colocalization with H3K27me3, but not with the Xi chromosome. As highlighted by whole genome microarray analysis of BAHD1 knockdown cells, BAHD1 represses several proliferation and survival genes, in particular the insulin-like growth factor II gene (IGF2). When overexpressed, BAHD1 specifically binds the CpG-rich P3 promoter of IGF2, which increases MBD1 and HDAC5 targeting at this locus. This region contains DNA-binding sequences for the transcription factor SP1, with which BAHD1 coimmunoprecipitates. Collectively, these findings provide evidence that BAHD1 acts as a silencer by recruiting at specific promoters a set of proteins that coordinate heterochromatin assembly.
G
ene repression in eukaryotes in response to developmental or environmental signals is a complex multistep process requiring the concerted action of many cellular factors, including DNA-binding transcription factors and cofactors. It also involves chromatin components and chromatin-binding/-modifying proteins, which are implicated in the establishment and maintenance of a condensed chromatin state, also referred to as facultative heterochromatin (1) . Deregulation of these chromatin regulatory factors and aberrant chromatin modifications play important roles in various human diseases, including cancers, developmental abnormalities, and neurologic disorders (2) (3) (4) (5) (6) . Moreover, several recent reports have linked histone modifications and infectious diseases (7) . During a screen for human proteins that interact with microbial factors and that might play a role in bacterial pathogenicity, we identified a putative chromatin-associated protein, bromo adjacent homology domaincontaining protein 1 (BAHD1), which remains uncharacterized. One study correlated repression of the BAHD1 gene to poor prognosis in lung cancer (8) , raising the possibility that BAHD1 might act as a tumor suppressor. This connection between BAHD1 and pathological processes prompted us to characterize the function of this protein.
BAHD1 is so named because it contains a C-terminal BAH domain, which is found in several chromatin-binding proteins involved in transcriptional repression (9) , including the yeast Sir3 protein (10) . We investigated whether BAHD1 could be involved in heterochromatin formation using a combination of approaches, including two-hybrid screen, knockdown, and gain-offunction experiments.
Results

BAHD1 Is a Nuclear Protein.
A single gene encodes BAHD1 in vertebrates, and no ortholog is found in invertebrates or plants, suggesting that BAHD1 is involved in vertebrate-specific functions. In addition to its C-terminal BAH domain, the BAHD1 protein contains a N-terminal proline-rich region and a central nuclear localization signal (Fig. 1A ). Immunofluorescence labeling with an antibody generated against the last 17 residues of the protein indicated that BAHD1 localizes to interphase nuclei in human cells ( Fig. 1 A) . But the staining was relatively weak, in agreement with the reportedly low BAHD1 gene expression in a broad range of human tissues (11, 12) . Consequently, we cloned BAHD1 cDNA into an expression vector. One day after transfection, BAHD1 tagged with the V5 epitope localized exclusively to the nucleus, whereas V5-tagged cyan fluorescent protein (V5-CFP), used as a control, localized to both the nucleus and the cytoplasm (Fig. 1 A) , confirming that BAHD1 is a nuclear protein.
V5-CFP (Fig. 1B) , demonstrating that BAHD1 associates with HP1␣ and MBD1.
BAHD1 Represses Basal Transcription. The chromatin-associated factors HP1␣ and MBD1 play key roles in the formation of repressive chromatin by binding methylated histone H3 and methylated DNA, respectively (14) (15) (16) . Consequently, we expected that BAHD1 would induce transcriptional repression. To test this hypothesis, BAHD1 was fused to the DNA-binding domain (DBD) of the GAL4 protein and coexpressed in HEK293 cells with reporters containing GAL4 binding sites linked to either TK or MMTV promoters upstream of the luciferase gene. GAL4-BAHD1 inhibited luciferase activity in a dose-dependent manner, with a repressive effect comparable to that of GAL4-HP1␣ and GAL4-MBD1 (Fig. S1 ). These results demonstrate that BAHD1 acts as a repressor when targeted to a promoter. Because BAHD1 can interact with heterochromatin factors, it may promote gene silencing through an heterochromatinization process.
Increasing BAHD1 Expression Levels in Cells Triggers Heterochromatin
Formation. An important feature of heterochromatin is its ability to spread from a specific nucleation site (14) . We reasoned that if BAHD1 promotes the assembly of a heterochromatinization machinery at genomic microdomains, then increasing its amount in cells should stimulate the spread of heterochromatin throughout large genomic regions, a phenomenon visible by microscopy techniques. To address this question, we expressed YFP-BAHD1 in human C3SV40 fibroblasts for 24 h or 48 h. YFP-BAHD1 localized in the nucleus as dispersed foci that increase in size with increasing YFP-BAHD1 expression to form larger structures (Fig. 1C) . Importantly, these structures were visible in living cells as patches of phase-dense material (Movie S1), which did not result from unspecific aggregation, because they were not observed on expression of either YFP or another tagged nuclear protein, such as GFP-PML (data not shown). To examine whether YFP-BAHD1-associated foci were heterochromatin areas, we first examined whether they correlated with histone hypoacetylation, a specific feature of heterochromatin (1) . Accordingly, acetyl-histone H4 was largely excluded from YFP-BAHD1 foci (Fig. 1D ). We then confirmed by electron microscopy that these nuclear structures were domains of condensed chromatin. In HEK293 cells expressing YFP-BAHD1, electron-dense patches of heterochromatin were visible throughout the nucleus, but were rarely detected in nuclei of untransfected cells (Fig. 1E ). Immunogold labeling further demonstrated that BAHD1 localized to this de novo-formed heterochromatin. In cells expressing V5-BAHD1, the V5 antibody reacted with electron-dense regions of condensed chromatin, but did not label nuclei of untransfected cells (Fig. 1 F and G) .
BAHD1 Directs HP1␣ at Specific Nuclear Sites. We next addressed whether BAHD1-mediated assembly of heterochromatin occurs after recruitment of chromatin modifiers by BAHD1 at specific nuclear sites, or vice versa. For this, we focused on HP1␣, whose localization within murine nuclei is well established. In interphase nuclei of murine cells, HP1␣ bound to histone H3 trimethylated at lysine 9 (H3K9me3) accumulates mainly at chromocenters (i.e., pericentromeric heterochromatin), which appear as distinct large heterochromatic bodies after DAPI staining or labeling with a specific H3K9me3 antibody (17) . In contrast, in murine nuclei expressing YFP-BAHD1, HP1␣ was displaced from chromocenters to YFP-BAHD1 foci ( Figs. 2A and S2 A) . In human cells-C3SV40 fibroblasts (Fig. 2B ) and JEG3 epithelial cells (Fig. S2B )-in which HP1␣ localizes at dispersed small nuclear foci, expression of YFP-BAHD1 also triggered important changes in HP1␣ localization, with its recruitment to BAHD1 foci. This HP1␣ relocalization to YFP-BAHD1-associated heterochromatin sites establishes that BAHD1 can displace and recruit HP1␣ in vivo, either directly or indirectly. 
Ectopically Expressed BAHD1 Colocalizes With Histone H3K27me3,
Including at the inactive X chromosome (Xi). Our initial two-hybrid screen suggested that BAHD1 could link chromatin condensation activities to DNA-binding transcription factors (Table S1) , thereby inducing the formation of facultative heterochromatin rather than constitutive heterochromatin at euchromatic loci. To test this hypothesis, we examined specific histone modifications that can distinguish between the 2 forms of heterochromatin (1) . We found that the YFP-BAHD1 heterochromatic foci overlapped mainly with H3K27me3, a specific feature of facultative heterochromatin, and overlapped only rarely with H3K9me3, found in constitutive heterochromatin (Fig. 2C ). In addition, as noted earlier, YFP-BAHD1 was not recruited at constitutive pericentromeric heterochromatin (Fig. 2 A) . Strikingly, when expressed in HEK293 cells, YFP-BAHD1 or V5-BAHD1 colocalized with H3K27me3 not only at heterochromatic foci dispersed throughout the nucleus, but also at 2 large bodies located at the nuclear periphery corresponding to 2 Xi (Movie S2; Fig. 2D ). Indeed, HEK293 are female cells with an atypical karyotype, usually containing 3 X chromosomes, 2 of which are inactive and visible as large heterochromatic bodies (18) . Through FISH, using as a probe the X-inactive specific transcript (XIST), an untranslated RNA that coats the Xi (18, 19) we confirmed that exogenous BAHD1 was recruited at these 2 Xi . V5-or YFP-BAHD1 localized at the 2 Xi in HEK293 cells (Figs. 2E and S2C), as well as at the unique Xi in diploid fibroblasts IMR90 and WI38 (data not shown). These findings indicate that BAHD1 is associated with facultative heterochromatin. They also suggest that it may target genes modified with H3K27me3, thus acting upstream or downstream of the histone H3 (K27) methyltransferase EZH2 of the polycomb (PcG) repressive complex PRC2, which catalyzes this histone modification (20) .
The BAH Domain Does Not Bind H3K27me3 In Vitro but Is Required for
BAHD1 Colocalization With H3K27me3
In Vivo. The BAH domain has been well characterized in the yeast Sir3 protein as a nucleosome and histone tail-binding domain (10) . To investigate whether the BAH domain of BAHD1 could directly bind H3K27me3, we used purified GST-BAH in binding assays with biotin-labeled histone H3 peptides (i.e., H3K27me3, H3K9me3, or unmodified H3 peptides) and histone H2B or H4 peptides. In contrast to GST-HP1␣, which strongly binds H3K9me3 through its chromodomain, GST-BAH did not specifically bind H3K27me3 (Fig. S3A) .
We next investigated whether the BAH domain could play a role in BAHD1 localization to H3K27me3 in vivo, by generating a truncated form of BAHD1 lacking the last 188 amino acids encompassing the BAH domain (BAHD1-⌬BAH). Because high expression of this YFP-tagged truncated protein in cells led to the formation of abnormal large nuclear bodies (data not shown), we further analyzed only those cells that moderately expressed BAHD1-⌬BAH. Strikingly, BAHD1-⌬BAH failed to localize with H3K27me3 at nuclear foci in C3SV40 male cells (Fig. S3B) and HEK293 female cells, except at the Xi chromosome (Fig. S3C) .
Taken together, our in vitro and in vivo results suggest that the BAH domain is necessary but not sufficient for BAHD1 colocalization with H3K27me3. In addition, recruitment of exogenous BAHD1 at the Xi chromosome does not require the BAH domain and may occur through interaction with Xi-specific components other than H3K27me3.
BAHD1 Depletion With siRNA Induces Expression of PRC2 Targets Such as IGF2. To identify genes targeted and repressed by BAHD1, we searched for genes induced in HEK293 cells depleted of endogenous BAHD1 with small interfering RNA (siRNA). Our analysis on whole human genome microarrays identified 192 transcripts induced by at least 1.4-fold in BAHD1 knockdown (KD) cells (Table  S2) . Differences in expression between control and BAHD1 KD cells were consistent with gene expression changes described in PcG-deficient cells (21) . The expression array data were then validated by quantitative real-time (qRT)-PCR analysis in independent experiments for a selection of several genes (Fig. S4 ). Of note, various proliferation and survival genes were induced on BAHD1 depletion; in particular, half of the genes associated with our data set and analyzed with the Ingenuity software were related to cell death, cellular growth and proliferation, and cancers (Table  S3 ). These data suggest that BAHD1 may directly silence several cancer-related genes.
According to the colocalization studies shown above, BAHD1 may target genes modified with H3K27me3. Thus, we compared the set of genes induced in BAHD1 KD cells with PcG targets previously identified in human embryonic fibroblasts (21) . We found that 35 genes induced on BAHD1 depletion overlapped with PcG targets (Table S3) . Interestingly, the gene most induced by BAHD1 depletion was the IGF2 gene, found as a PRC2 target in several genome-wide mapping studies (21) (22) (23) . Like BAHD1, IGF2 is specific to vertebrates. It encodes a growth factor that plays a key role in fetal growth and influences body mass in adults (24) . Moreover, IGF2 overexpression correlates with carcinogenesis (3, 24, 25) . We thus addressed whether BAHD1 directly regulates IGF2.
BAHD1 Binds the IGF2 P3 Promoter Region and Represses IGF2 and
IGF2AS. In humans, IGF2 regulation is a complex process involving 5 different promoters (Fig. 3A) in a tissue-and developmentspecific manner (26) . IGF2 is also submitted to genomic imprinting via transcriptional repression of the maternal allele (3, 24, 26) . IGF2 imprinting involves differential methylation of CpG islands between the 2 parental alleles (DMR), 1 of which-the imprinted control region (ICR)-is an insulator located upstream of the adjacent imprinted gene H19 (Fig. 3A) (3, 24, 26) . Because BAHD1 interacts with the methyl-CpG binding protein MBD1, and because of the importance of CpG methylation in IGF2 expression, we investigated whether BAHD1 directly binds IGF2 at CpG islands in HEK293 cells. In these cells, IGF2 expression is governed mainly by promoter 3 (P3), the most active promoter in fetal and nonhepatic adult tissues (27) and the major up-regulated promoter in many tumor tissues (25, 28) . We performed chromatin immunoprecipitation (ChIP) from cells expressing V5-BAHD1 or the control V5-CFP, using the V5 antibody (which is efficient in ChIP assays) or mouse IgG to control nonspecific binding. Three DNA fragments present in the 2 CpG islands located upstream of P3 (P3a, P3b, and P3c) were selectively enriched in ChIP samples from V5-BAHD1-transfected cells, whereas no specific binding of BAHD1 was observed elsewhere in the IGF2/H19 region (Fig. 3B) . BAHD1 binding to the P3 region was correlated with repression of IGF2, as demonstrated by a 40% decrease in IGF2 transcript level in BAHD1-overexpressing cells. In contrast, overexpression of the truncated BAHD1-⌬BAH did not repress IGF2, suggesting that the BAH domain is required for BAHD1 silencing function (Fig. 3C ). In cells depleted of endogenous BAHD1, the increased amount of IGF2 transcript was correlated with decreased expression of BAHD1 (Fig. 3D ). Taken together, our results strongly suggest that BAHD1 promotes heterochromatinization at the P3 proximal region, thereby repressing transcription of IGF2.
The CpG-rich region upstream of P3 contains several potential binding sites for transcription factors regulating IGF2, as well as regulatory elements for IGF2AS, an antisense transcript of IGF2 also expressed on the paternal allele and targeted by PRC2 (Fig.  3A ) (21) (22) (23) 29) . We reasoned that if BAHD1 promotes heterochromatinization at P3, then it also should repress IGF2AS expression. In agreement with this hypothesis, we found that IGF2AS transcript level significantly increased on BAHD1 depletion with siRNA ( Fig. 3D) . Together, these results demonstrate that BAHD1 physically interacts with the CpG-rich P3 regulatory region and represses IGF2 and IGF2AS transcription.
BAHD1
Coimmunoprecipitates With MBD1, HDAC5, and SP1. We explored whether transcription factors known or predicted to regulate P3, including AP2, SP1, EGR1, MEF2, TEF1, and HAND1 (Fig.  S5) , are connected to BAHD1 through protein-protein interactions. We extended the network of interactions obtained in our two-hybrid screen to known interactors of BAHD1 partners, reported in Ingenuity and HPRD knowledge databases. Strikingly, this global analysis demonstrated a network in which BAHD1 couples chromatin modifiers to transcription factors able to target promoter P3 ( Fig. S5 ; Table S1 ). This network also connects BAHD1 to EZH2 and to the PRC1 ubiquitin ligase RING1b (20) , supporting a link between BAHD1-and PcG-mediated silencing ( Fig. S5 ; Table S1 ).
We then used coimmunoprecipitation to address whether BAHD1 could interact in vivo with some of these proteins. Nuclear extracts from HEK293 cells expressing either V5-BAHD1 or control V5-CFP were immunoprecipitated with the anti-V5 antibody or with control IgG, and the immunoprecipitates were probed for the presence of HDAC5, MBD1, SP1, and AP2. HDAC5, MBD1, and SP1 clearly coimmunoprecipitated with V5-BAHD1 but not with the control V5-CFP (Fig. 4A) . In contrast, no signal of AP2 copurifying with V5-BAHD1 was detected (data not shown). These results indicate that ectopically expressed BAHD1 forms a complex with chromatin regulatory proteins and at least one transcription factor (SP1). Increasing BAHD1 Expression Induces MBD1 and HDAC5 Recruitment at IGF2 P3. To provide evidence that BAHD1 mediates gene silencing by recruiting heterochromatin factors to specific loci, we examined MBD1 and HDAC5 recruitment at the IGF2 promoter P3 in BAHD1-overexpressing cells. In these cells, exogenous BAHD1 is recruited at P3 (Fig. 3B) , represses IGF2 expression (Fig.  3C ) and coimmunoprecipitates with MBD1 and HDAC5 (Fig. 4A) . As demonstrated by ChIP assays, increased MBD1 and HDAC5 recruitment at the P3b region of IGF2 occurred on BAHD1 ectopic expression (Fig. 4B) . These results strongly suggest that targeting BAHD1 to a specific locus triggers the recruitment of heterochromatin factors.
Discussion
In this work, we have demonstrated through multiple approaches that BAHD1 is a new factor involved in heterochromatin formation in vertebrates. We propose that BAHD1 acts as a silencer that connects heterochromatin factors, such as HP1, MBD1, and HDAC5, to DNA-bound transcription factors, such as SP1, to repress transcription at specific euchromatic loci. Our data strongly suggest that BAHD1 targets include several genes previously associated with the H3K27me3 mark, including IGF2 (21-23). Our findings also provide evidence for a role of the conserved BAH domain in subnuclear localization of BAHD1 and silencing. We also found that when ectopically expressed, BAHD1 is targeted to the Xi in female cells independent of the presence of the BAH domain, an important issue to be addressed in future work.
The massive chromatin compaction triggered by BAHD1 overexpression in cells suggests that BAHD1 may spread along the chromatin fiber, as reported for the yeast BAH-containing protein Sir3 (10) . Like Sir3, BAHD1 may interact directly with nucleosomes through its conserved BAH domain; however, the BAH domain does not specifically bind H3K27me3, at least in vitro, suggesting that it does not function as the chromodomain of HP1 or PcG proteins in recognizing methylated histone H3. Nevertheless, the BAH domain is important for BAHD1 colocalization with H3K27me3 in vivo, as well as down-regulation of IGF2 levels. These findings generalize the role of BAH domains in silent chromatin assembly.
Based on the reported functions of chromatin proteins found in the BAHD1 interactome ( Fig. S5 ; Table S1 ), as well as on the fact that BAHD1 ectopic expression is sufficient to induce massive heterochromatinization and endogenous BAHD1 depletion induces expression of IGF2 and IGF2AS, we propose a model that explains how the BAHD1-containing complex triggers IGF2 silencing. BAHD1 is first targeted to the IGF2-IGF2AS overlapping regulatory region through selective binding to cofactors of transcription factors (Fig. 5) . BAHD1 then orchestrates the assembly of a chromatin condensation machine by sequential recruitment of at least HP1 (which binds methyl-H3K9), MBD1 (which binds methylCpG), and the histone deacetylase HDAC5, to stimulate heterochromatin nucleation and spreading, as detailed in Fig. 5 . More work is needed to validate the presence in the BAHD1 multiprotein complex of several key regulators found in our two-hybrid screen, such as the histone methyltransferase KMT1E and the nucleosome remodeler CHD1, as well as to search for a possible link to DNA methylation and RNA processing. Another important issue is the connection between BAHD1 and PcG repressive complexes (20) . Whether BAHD1 acts upstream or downstream of EZH2 that Hypothetical model for BAHD1-mediated heterochromatic silencing at the IGF2 P3 region. 1, BAHD1 targets IGF2 P3 by interacting with cofactors of DNA-bound transcription factors. 2, BAHD1 recruits KMT1E, which methylates K9 of histone H3 (H3K9me). HP1 is tethered to chromatin by binding H3K9me and BAHD1. EZH2 is recruited at this locus, before or after BAHD1, by an unknown mechanism and methylates K27 of H3 (H3K27me). 3, KMT1E and HP1 interact with DNMT3, which methylates cytosines (meCpG), creating binding sites for MBD1. BAHD1 recruits HDAC5 and CHD1, both of which bind NCOR1, which interacts with SP1. HDAC5 also binds MEF2. The complex is stabilized by cross-interactions between BAHD1, MBD1 and HDAC5 (Fig. S5 ). HDAC5 and CHD1 activities lead to histone deacetylation and nucleosome compaction. 4, Heterochromatin spreads to surrounding sequences after successive loading of BAHD1, histone, and DNA methylation marks, preventing access of the transcription machinery to the promoter and resulting in transcriptional repression of IGF2 and IGF2AS. Abnormal down-regulation of BAHD1 would reactivate IGF2 expression. forms H3K27me3, and whether components of PRC1, which bind this mark, are associated with BAHD1 heterochromatic foci remain to be addressed (Fig. S5) .
We propose that BAHD1 belongs to a growing family of scaffold proteins, including Sin3, Kap1, MTA, and MTG proteins (13, (30) (31) (32) , that tether chromatin-modifying enzymes to sequence-specific transcription factors, thus enabling local chromatin regulation at specific gene targets. Pathological deregulation of such scaffolds is likely to have deleterious effects. Of note, BAHD1 expression is down-regulated in invasive lung cancer cells (8) , and a recent study indicated reduced levels of BAHD1 transcript in RNA in blood samples from patients with double tumors compared with patients with single tumors (http:// www.nextbio.com/b/home/home.nb?q ϭ BAHD1). Our findings support the hypothesis that BAHD1 acts as a tumor suppressor through the silencing of cancer-related genes, such as IGF2, in adult tissues. Further studies are needed to address this possibility, and also to explore a putative relationship between BAHD1-induced silencing and IGF2 imprinting.
Materials and Methods
Cell Lines, Plasmids, Antibodies, siRNA, and Oligonucleotides. The cell lines, plasmids, antibodies, siRNA, oligonucleotides, and transfection procedures used in this study are described in SI Materials and Methods, 
Top Molecular and Cellular Functions associated to genes induced in BAHD1 KD cells (Ingenuity Pathways Analysis).
Category Molecules p-value # Molecules
Cell Death SAT1, IL6R, PRKAR1A, PHLDA2, RASL10A, PHLDA1, S1PR3,  DSP, IGF2, ADCYAP1R1, ALOX5, QKI, LGALS3, RIPK2,  IGFBP7, RUNX2, CDKN1C, PLA2G7, STEAP3, F2R, PLAU,  SULF1, KAT2B, RET, BCL2L11, CTH, ATF1, RBL1, DACH1,  RTN1, GAL, VCAN, PACS2, TAC1, SUMO1, HLF, EMP2,  CLEC11A, TANK, ACSL4, TIMP2, INDO   1,56E-04 -1,90E-02  43   Cellular Growth and Proliferation  F12, SAT1, IL6R, PRKAR1A, SEC14L2, PHLDA2, RASL10A,  PHLDA1, DSP, S1PR3, IGF2, CRLF1, ADCYAP1R1, ALOX5,  LAMB1, LGALS3, RIPK2, IGFBP7, ITCH, RUNX2, CDKN1C,  STEAP3, KISS1R, F2R, BLZF1, PLAU, TACC2, KAT2B,  BCL2L11, RET, CTH, RBL1, CACNA1G, DACH1, GDF11,  TFAP2C, GAL, VCAN, TAC1, SUMO1, TACSTD1, CLEC11A,  EMP2, TIMP2, , and GST (Novagen). The anti-BAHD1 was generated against a peptide corresponding to the last 17 amino acids of BAHD1 and was affinity-purified.
Plasmids and Cloning Strategies. To clone BAHD1 cDNA, total RNA was purified from 1 ϫ 10 7 JEG3 or HEK293 cells using the Qiagen RNeasy Mini Kit, and cDNAs were amplified using the SuperScript III First-Strand synthesis system and Platinum Taq polymerase high fidelity (both from Invitrogen) according to the manufacturer's protocol. The PCR fragments were directly subcloned, using a directional topoisomerase cloning system, into the mammalian expression vector pcDNA3.1/V5-His-TOPO (Invitrogen), leading to pcV5-BAHD1 vectors. Both sequences were identical to the published sequence (accession number NM014952; gene ID 22893) with one D182H modification corresponding to a single nucleotide polymorphism described previously (http://www.ncbi.nlm.nih-.gov/projects/SNP; rs17856679). The control plasmid pcV5-CFP was constructed by inserting the sequence encoding the CFP from pE-mCFP-N1 (3) in pcDNA3.1/V5-His-TOPO. The plasmid pcV5-BAHD1 was used to amplify and subclone full-length BAHD1 into pB27 (Hybrigenics), pE-citrine-N1 (4), or pSG424-GALM, or only the sequence encoding the last 193 amino acids of BAHD1 (aa 587-780) into pET41a(ϩ) (Novagen), with the primers and restriction enzymes indicated below. pE-citrine-N1 encodes cYFP, a variant of YFP with better photostability than other YFP variants (4). The pSG424-GALM vector, which allows the expression of GAL4 (1-147) fusions in mammalian cells, is derived from pSG424 (5) modified to contain additional restriction sites (NdeI/NcoI/ PstI/BsteEII) in the polylinker cloning site. pGEX-MBD1 and pGAL-MBD1 were generated by PCR amplification of human MBD1 cDNA (splice variant 3) from an EST clone (IM-AGE:5432943) in vector pGEX2T (Amersham Pharmacia) or pSG424-GALM. pGEX-HP1␣ and pGAL-HP1␣ were generated by PCR amplification of human HP1␣. pMMTV-Luc was constructed by cloning a GAL-binding site in the SacI site of the MMTV promoter in pFc31Luc (6) . The pG5TK-Luc was a kind gift from J. G. Judde, and the plasmid pcDNA3 encoding GFP-PML (variant IV) was a kind gift from O. Bischof. All constructs were verified by double-strand sequencing. The plasmids and oligonucleotides used are listed in Table S4 .
Identification of BAHD1 Interactors by Yeast Two-Hybrid Screening
and Construction of an Interaction Network. The bait construct was BAHD1 cloned in pB27, a Y2H vector optimized by Hybrigenics (http:/www. hybrigenics.com). pB27-BAHD1 was transformed in the L40DGAL4 yeast strain (7), and Y2H screening was performed by Hybrigenics. A human placenta random-primed cDNA library (RP4) transformed into the Y187 yeast strain and containing 10 million independent fragments was used for mating. High mating efficiency was ensured by using a specific mating method (7). The screen was first performed on a small scale, to adapt the selective pressure to the intrinsic property of the bait. Neither toxicity nor autoactivation of the bait was observed. Then the full-scale screen was performed under conditions ensuring that a minimum of 50 million interactions were tested, to cover 5 times the primary complexity of the yeast-transformed cDNA library (8) . A total of 54.96 million interactions were actually tested. After selection on medium lacking leucine, tryptophane, and histidine, positive clones were chosen, and the corresponding prey fragments were amplified by PCR and sequenced at their 5Ј and 3Ј junctions. Sequences were then filtered and contiged as described previously (9) and compared with the latest release of the GenBank database using BLAST (10) . For all nuclear preys, the predicted interaction was weak, as identified through a unique prey fragment or multiple identical fragments.
To generate the BAHD1 interactome, we used data from our whole human genome Y2H screen, as well as data obtained in a Y2H screen of pairwise interactions between 7,200 human protein-encoding genes (11) , in which BAHD1 partners, such as MDFI and DVL3, were found. All BAHD1 interactors were uploaded in the Ingenuity Pathways Analysis software (www.ingenuity.com) to create a network of direct protein-protein interactions. All proteins were also checked for interactors, one-by-one, in the Human Protein Reference Database (http:// www.hprd.org).
Transient Transfections With Plasmids or Oligofection With siRNA
Duplexes. Transient transfections were performed as described previously (12) using lipofectamine 2000 or LTX (Invitrogen) according to the manufacturer's protocol. To knock down expression of BAHD1, HEK293 was transfected with chemically synthesized siRNAs (Ambion) using lipofectamine RNAi max (Invitrogen) following the manufacturer's instructions. A combination of 3 different siRNA duplexes (in microarray experiments) or individual siRNA BAHD1 1 or 2 (in qRT-PCR assays) was used.
The silencer negative control 1 siRNA (Ambion #4611) was used as a control. The silencing efficiency of these siRNAs was examined by RT-PCR or qRT-PCR (see Table S5 ) at 72 h posttransfection. The RT-PCR procedure used a SuperScript One-Step RT-PCR (Invitrogen) with serial dilutions of the RNA template, according to the manufacturer's protocol, and the following primers: for BAHD1, forward, atgcttcctgagggcaagctgtcc; reverse, gtaagtgctcaggtctgtaatacc; for GAPDH, forward, gtcgtattgggcgcctggtcac; reverse, cacgacgtactcagcgccagca. siRNA treatment did not alter cell morphology or growth.
Immunofluorescence Analysis, Live Cell Imaging, and Image Processing. Cells were fixed for 20 min at room temperature with 3% or 4% paraformaldehyde in PBS, permeabilized with 0.4% or 0.5% Triton X-100 in PBS for 4 min at room temperature, blocked in PBS containing 1% BSA (Sigma), and, when indicated, incu-bated with primary antibodies for 1 h and then with secondary antibodies for 1 h. The secondary antibodies used were Alexa 488-conjugated (Molecular Probes) or Cy3-, Texas red-, or Cy5-conjugated (Jackson IR) goat anti-mouse or anti-rabbit IgGs antibodies. Nuclei were visualized in phase contrast and with DAPI. The preparations were examined with a Zeiss Axiovert 200M epifluorescence microscope, connected to a cooled CCD camera (CoolSNAP HQ ; Photometrics), or with a Zeiss LSM 510 confocal laser scanning microscope. Images were acquired with apochromat 63ϫ or 100ϫ (NA 1.4) objective lenses and processed using MetaMorph version 6.1 (Universal Imaging) or Zeiss LSM Image software. For live cell imaging, images were acquired with a microscope equipped with a temperature-controlled stage and an objective heater (Biotechs). Fluorescent illumination was driven by an ultra-highspeed wavelength switcher (Lamda DG4; Sutter Instrument) equipped with a 175-W xenon arc lamp and excitation filters for YFP (Chroma Technology). Emission filters were selected using a high-speed Lamda 10 filter wheel (Sutter Instrument). For 3D reconstruction of BAHD1 foci in the nucleus, HEK293 cells expressing V5-BAHD1 were fixed, stained with DAPI and V5 antibody, and analyzed with a Zeiss LSM-510 confocal microscope. Stacks of confocal images were deconvoluted with Huygens software (Scientific Volume Imaging) and processed with OsiriX software (13) . DAPI staining was used to define the nucleus volume. The V5 staining was threshold compared with the V5 staining in untransfected HEK293 cells.
RNA FISH.
A DNA probe detecting Xist RNA was nick-translated using plasmid G1A (from the fourth intron to the 3Ј end of the human Xist gene), a Nick-translation kit (Abbot), and spectrumred-dUTP (Abbot). After the addition of human COT-1 (Invitrogen) and tRNA (Roche), the labeled probe was precipitated with ethanol, resuspended in formamide (Sigma), and denatured for 10 min at 80°C. Cell cultures on coverslips were fixed in 3% paraformaldehyde for 10 min and permeabilized with 1ϫ PBS/ 0.5% Triton X-100 for 4 min. Cells were blocked with PBS, 1% BSA, tRNA, and RNAguard (Amersham), and then dehydrated in ethanol. Cells were then incubated overnight at 37°C in a hybridization mixture containing denaturated probe, 0.75% BSA, 2ϫ SSC, 10% dextran sulfate, and vanadyl ribonucleoside complex (Biolabs). After washes in 2ϫ SSC/50% formamide, in 2ϫ SSC, and then in 1ϫ SSC, coverslips were mounted on slides with antifading solution containing DAPI.
Transmission Electron Microscopy. HEK293 cells were transfected with the YFP-BAHD1 expression vector and then either directly fixed or sorted by FACS to enrich for YFP-BAHD1-positive cells (at 488-nm excitation) and expanded overnight before fixation. Both procedures gave similar results, except that the sorted cells appeared deformed and rounded. Untransfected and transfected cells were fixed in 2.5% glutaraldehyde and postfixed with 1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4). The cells were stained en bloc with 2% uranyl acetate in 30% methanol, then dehydrated in a graded series of ethanol solutions, before being embedded in Epon resin and undergoing polymerization at 60°C. Ultrathin sections were obtained using a Leica Ultracut UCT microtome and were stained with 4% uranly acetate with lead citrate before being viewed under a JEOL JEM1010 microscope at 80 kv accelerating voltage.
For the immunogold labeling experiments, cells transfected with V5-BAHD1 expression vector and untransfected cells were fixed with 0.1% glutaraldehyde-4% paraformaldehyde in 0.1 M Sörensen buffer (pH 7.2). Remaining free aldehyde groups were quenched with 0.25% NH 4 Cl in 0.1 M Sörensen buffer. Cells were embedded in 4% Agar type 9 diluted in water, stained en bloc with 0.5% uranyl acetate in water, dehydrated according to the progressive lowering of temperature (PLT) method (14), embedded in Lowicryl K4M resin, and polymerized under UV light. After sectioning, as described above, immunolabeling was performed with the Leica EM IGL automated Immunogold labeling system according to the protein A gold method (15), using monoclonal anti-V5 antibody and protein A coupled to 10-nm colloidal gold particles (at Utrecht University Medical Center). Sections were viewed as above.
Protein Purification, Preparation of Nuclear Extracts, GST Pull-Down and Histone Peptide-Binding Assays, IP, and Immunoblotting. To purify GST-tagged proteins, pET41-BAH or pGEX plasmids encoding HP1␣ or MBD1 were transformed in Escherichia coli BL21(DE3), and the GST fusion proteins were produced and purified following standard procedures (Novagen or Amersham Pharmacia Biotech). Histone peptide-binding assays were performed as described previously (16) . In brief, 1.0 g of a biotinylated histone peptide (12-403, 12-405, 12-407, 12-408, 12-565, or 12-568; Millipore) or a biotinylated positively charged control KK-peptide (KPKKAAPKKK-biotin; Eurogentec) was incubated with 1 g of protein in binding buffer [50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 0.1% Nonidet P-40, 1 mM PMSF, plus protease inhibitors] overnight at 4°C with rotation. After a 1-h incubation with avidin beads (Amersham) and extensive washing, bound proteins were analyzed by SDS/PAGE and Western blotting with anti-BAHD1 or anti-HP1␣ antibodies. For pull-down assays, 100 L of a 50% slurry of gluthatione Sepharose 4B beads (Amersham) was mixed with each bacterial lysate for 4 h at 4°C. The resin was collected and washed 3 times with supplemented PBS and then resuspended in 1 mL of binding buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 0.5% Nonidet P-40] supplemented with protease inhibitor mixture. The amounts of GST fusion proteins were estimated by either Western blot analysis or Coomassie brilliant blue staining for normalization of quantities used in the pull-down assay. Nuclear extracts from 4 ϫ 10 7 HEK293 cells transfected or not transfected with pcV5-BAHD1 or pcV5-CFP expression vectors were purified using a Active Motif Nuclear Extraction Kit following the manufacturer's instructions. Here 50 L of purified nuclear extract including V5-BAHD1 or V5-CFP was mixed with appropriate quantities of GST fusion protein resin in supplemented binding buffer overnight at 4°C. The beads were then washed twice with the same binding buffer and once with binding buffer without the protease inhibitor mixture. Then 20 L of SDS/PAGE loading buffer was added, and the mixture was boiled for 6 min. After centrifugation at 2500ϫ g for 5 min, 15 L of the supernatant was subjected to SDS/PAGE and Western blot analysis using Hybond membranes (Amersham) and a Pierce detection kit. IP experiments were performed with the Active Motif Nuclear Complex Co-IP Kit. For each IP, 500 g of nuclear extracts prepared following the manufacturer's instructions was diluted in low-IP buffer supplemented with 150 mM NaCl and 0.2% detergent, and then incubated with 5 g of V5 mAb or mouse IgG. Complexes were recovered with 50 L of magnetic beads (Dynabeads protein G; Invitrogen), washed 5 times in IP buffer, resuspended in 20 L of sample buffer 2X, and processed for SDS/PAGE and transfer on PVDF membranes. Detection was performed using Amersham ECLϩ chemiluminescence reagents.
Luciferase Reporter Assays. HEK293 cells were transfected with the indicated luciferase reporters (100 ng/24-well plate) together with GAL expression constructs, as shown in Fig. S1 . When required, the total amount of DNA was kept constant with a pCDNA vector (Invitrogen). pCMV-Renilla luciferase (2 ng/24-well plates; Promega) was included in all transfections to control for transfection efficiency. When the MMTV-luc reporter was used, cells were treated with dexamethasone 1 M overnight before protein extraction. Firefly and Renilla luciferases were measured at 48 h after transfection using Promega luciferase assay reagents according to the manufacturer's instructions. Protein content was measured using Bradford reagent (BioRad). Luminometer readings were expressed as arbitrary units and expressed as the percentage of an appropriate control, as indicated in Fig. S1 . All transfection experiments were carried out in triplicate wells and repeated 2 or 3 times.
Microarray Analysis. Total RNA from cells transfected for 72 h with siRNA BAHD1 or siRNA control was extracted and purified using the Qiagen RNeasy Kit. The quality of RNAs and cRNAs was monitored on Agilent RNA Nano LabChips. RT-PCR on 5 g of total RNA using oligo(dT) primers and in vitro transcription of the cDNA in presence of biotin were done using a Affymetrix GeneChip Amplification One-Cycle Target Labeling Kit according to standard protocols. Fragmented, biotinlabeled cDNA samples were hybridized on Array Type GeneChip Human Genome U133Plus 2.0. For each condition, 3 biological replicates were hybridized. Data and statistical analysis were performed as described previously (17) , with the following modifications. GeneChip Operating Software (GCOS; Affymetrix) was used to generate the report (RPT) files containing the hybridization quality control (QC) metrics for each GeneChip of the experimental design. Thereafter, hybridization quality was assessed by uploading all of the RPT files with the AffyGCQC Web-based interface (Osorio) to visualize the Affymetrix-recommended metrics with a graphical representation and to identify potential deviating measures with an outlier detection statistical test. GCOS software determines a detection call (absence/presence) using Wilcoxon statistics for each probe set. The fold changes of the differentially expressed genes after P value adjustment (threshold, .05) were analyzed by filtering the data set with a threshold of Log2 ratio ϭ 0.5 (1.4-fold change). Additional filtering was applied so that ''unknown'' transcripts, redundant probe sets, and genes called ''absent'' in all 6 chips were removed. The data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO series accession number GSE16097 (http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc ϭ GSE16097).
Data were uploaded in the Ingenuity Pathways Analysis software (www.ingenuity.com). Genes from the data set that were associated with networks, biological functions, and/or diseases in the Ingenuity Pathways Knowledge Base were considered for the analysis. For generation of networks, genes of the data set, called focus genes, were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Networks of these focus genes were then algorithmically generated based on their connectivity. The functional analysis identified the most significant biological functions and/or diseases to the data set. Fisher's exact test was used to calculate a P value determining the probability that each biological function and/or disease assigned to that data set was due to chance alone.
RNA Isolation, RT-PCR, and Analysis of Transcript Levels. RNA from cells was extracted using the Qiagen RNeasy Kit. cDNA preparation and qPCR assays were carried out by Cogenics (www-.cogenics.com), as follows. RNA was treated with TURBO DNA-free DNase (Applied Biosystems) using 2 g of total RNA in a volume of 10 L. cDNA was obtained by reverse transcription of the DNAse-treated RNA using an Applied Biosystems high-capacity cDNA Archive Kit with random primers in a final volume of 50 L, as recommended by the manufacturer. Primers for SYBR Green chemistry qPCR were designed using a homemade script. Two primer sets per transcript were designed. PCR specificity and efficiency were checked for each primer set using serial dilutions of cDNA. RT-PCR was performed using Power SYBR Green Master Mix-specific primers (400 nM; Applied Biosystems) and cDNA (volume corresponding to 10 ng of total RNA). Taqman Gene expression assays were purchased from Applied Biosystems, and PCR was performed using Applied Biosystems Taqman Universal PCR Master Mix as recommended by the manufacturer. Thermocycling was performed using an Applied Biosystems ABI 7500 Real-Time PCR System. For SYBR Green chemistry and Taqman assays, each measurement was carried out in triplicate. Relative expression quantification was calculated with the 7500 Fast System software using the comparative ⌬⌬Ct method. The internal control gene was HPRT, 18S, or GAPDH, depending on the experiment. The stable expression levels of these housekeeping genes have been validated previously. The range of minimum and maximum fold changes was determined based on the SDs. Statistical significance of the difference in mean expression of genes was evaluated using the Student t test; a P value Ͻ .05 was considered significant. The primers used are listed in Table S5 .
Quantification of IGF2 Relative to BAHD1 Transcript Levels. To differentially modulate the amount of BAHD1 in cells, HEK293 cells were transfected with V5-BAHD1 for 48 h to increase BAHD1 expression or with BAHD1 siRNA #1 or #2 for 48 h or 72 h to differentially decrease BAHD1 expression. Controls were V5-CFP expression vector or siRNA #1 (Ambion #4611), respectively. V5-BAHD1 and V5-CFP transfection efficiencies were evaluated by immunofluorescence using anti-V5 antibody and were found to be Ϸ70% of total cells. After RNA extraction, the levels of BAHD1 and IGF2 transcripts were quantified by qRT-PCR using GAPDH as an internal control, as described earlier.
ChIP and Site-Specific PCR Analysis. We performed ChIP on HEK293 cells transfected for 24 h with V5-BAHD1 or V5-CFP expression vectors. For each vector, the number of transfected cells, evaluated by immunofluorescence using anti-V5 antibody, was Ϸ70% of total cells. Three independent chromatin preparations per vector, each corresponding to 10 7 cells, were made, immunoprecipitated in duplicate, and quantified in duplicate. Formaldehyde-fixed cells were extracted with 10 mM Tris-HCl (pH 8), 1 mM EDTA, 0.5 mM EGTA, 0.25% (vol/vol) Triton X-100, and protease inhibitors for 5 min on ice. The pellets were then reextracted with TNEN 250 plus inhibitors for 30 min on ice. The resulting pellets were resuspended in 10 mM Tris-HCl (pH 8), 1 mM EDTA, 0.5 mM EGTA, and 0.5% (wt/vol) SDS, and then sonicated to shear chromatin to a final size of 200-500 bp. Extracts were quantified by DO 260 nm to adjust the quantities of material and then diluted to obtain the following buffer composition: 0.1% (wt/vol) SDS, 1% (vol/vol) Triton, 0.1% (wt/vol) sodium deoxycholate, 10 mM Tris-HCl (pH 8), 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, and protease inhibitors. IP was carried out overnight at 4°C with V5 antibodies or control mouse IgG, or with MBD1 or HDAC5 antibodies or control rabbit IgG. The immunocomplexes were recovered with protein G magnetic Dynabeads (Invitrogen) added for 90 min and then washed 5 times in a succession of isotonic and salt buffers (composition available on request) using a magnet system. After a final wash in TE, bound material was eluted by the addition of water containing 10% (wt/vol) Chelex, followed by boiling for 10 min to reverse cross-linking, incubation with proteinase K (100 g/mL) for 30 min at 55°C with some shaking, boiling for another 10 min, and finally centrifugation to collect the bound fraction in the supernatant. Aliquots were used for qRT-PCR performed with a Stratagene Mx3005p with SYBR Green kits according to the manufacturer's instructions. The primers were designed using PrimerQuest (www.idtdna.com) with the following advanced settings: Tm ϭ 60°C Ϯ 1°C; %GC, 50%; length, 20-25 nucleotides; amplicon size, 75-250 bp. The primer sequences used are given in Table 5 . Data were computed as described previously (18) . The PCR efficiency (E) was estimated by sequential dilution of the inputs, followed by amplification with each primer set corresponding to the different amplified genomic regions. The slopes of these curves were then used to calculate the E value as follows: E ϭ 100 ϫ (Ϫ1 ϩ 10 (Ϫ1/slope) ). All PCR efficiencies were 90%-100%. Because CpG-rich sequences are difficult to amplify, several pairs of primers were tested by dissociation curve and electrophoresis analysis to select those that gave only a single product by PCR. The values of each PCR for the recruitment of the V5 antibody on chromatin were calculated using the nonimmune IgG antibody on the same chromatin extract as a reference. The measured ''cycle thresholds'' (Ct) were used to calculate the relative recruitment (R) of the V5 antibodies as follows: RV5 ϭ (1 ϩ E/100)ˆ(CtIgGCtV5). As control for the specific presence of BAHD1 along the IGF2 gene in the V5-BAHD1-transfected cells, the same ChIP experiments were conducted on chromatin from cells transfected with plasmid expressing V5-CFP. In addition, the RV5 observed on the CD44 promoter in the V5-BAHD1-and V5-CFPtransfected cells was used to set the reference (RIgG) of the relative recruitment at 1. The CD44 promoter region was used for 2 reasons: (i) The expression of this gene was not modified on treatment by the BAHD1 siRNA, and (ii) this gene is located on the same chromosome as IGF2, and the amplified region lies within a CpG island, as does the IGF2 P3. The data presented are representative of 3 independent experiments and are averages (Ϯ SD) of qPCR replicates. Binding of AP2 to IGF2 P3 has been reported previously (53, 55) . (B) A network highlighting possible interactions among BAHD1, chromatin regulatory proteins, and IGF2 transcription factors. Direct BAHD1 interactors identified in yeast two-hybrid screening (within the white circle) were connected to partners (in the gray square) using the Ingenuity and HRPD knowledge bases. Proteins are represented as nodes, and protein-protein interactions between 2 nodes are represented as edges (lines). Arrows indicate formation of chromatin modifications. All edges and arrows are supported by experimental work described by at least one reference in the literature. Blue lines connect components that bridge BAHD1 to SP1. Red lines connect components involved in chromatin condensation, and red arrows indicate chromatin modification activities, generating H3 methylation at K9 (H3K9me) or at K27 (H3K27me), H4 deacetylation (deAc-H4), H2A ubiquitylation (Ub-H2A), or CpG methylation (meCpG). Dashed lines indicate potential interactions (37) . Protein names, functions, and references are given in Table S1 .
Movie S1 (AVI)
Movie S1. Increasing BAHD1 expression stimulates the formation of phase-dense nuclear structures in living cells. C3SV40 living cells untransfected or transiently transfected with plasmid encoding YFP-BAHD1 (for 24 h or 48 h) were placed under a microscope at 37°C, and image series were collected every 30 s for 30 min. After a short (24 h) transfection time, YFP-BAHD1 localized in the nucleus as small dispersed and dynamic foci that increased in size on increased transfection time (48 h) to form static larger structures, visible in phase contrast as patches of dense material, and in electron microscopy as heterochromatin areas (see Fig. 1 ). (Scale bar: 10 m.) Table S1   Table S2   Table S3   Table S4   Table S5 Movie S2. Spatial localization in 3D of exogenous V5-BAHD1 in a HEK293 cell nucleus. V5-BAHD1 accumulated at the 2 Xi chromosomes located at the nuclear periphery and at foci dispersed in the nucleus in a HEK293 cell. Deconvoluted confocal series images of cross-sections of a cell transfected with V5-BAHD1 expression vector were reconstructed in 3D using OsiriX software. V5-BAHD1 is labeled in green, and the nucleus volume is labeled in gray.
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